Generation Bio, a Cambridge, MA-based gene therapy company, closed a $110m Series C financing.
The round was led by T. Rowe Price funds and accounts, with participation from Farallon, Wellington Management Company and existing investors Atlas Venture, Fidelity, Invus, Casdin, Deerfield, Foresite Capital and an entity associated with SVB Leerink.
The company intends to use the funds to advance its two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-enabling studies and clinical development.
Led by Geoff McDonough, M.D., president and chief executive officer, Generation Bio is a biotechnology company leading a new generation of re-dosable long-lasting gene therapy. Its non-viral platform combines three technologies: a novel cell-targeted lipid nanoparticle delivery system (ctLNP), a proprietary closed-ended DNA construct (ceDNA) and a high-capacity capsid-free biologics manufacturing process. In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio is developing gene therapies for patients with diseases of skeletal muscle and the eye.
The company was founded by Atlas Venture.